TecDAX
Infineon’s €225 Million Buyback Signals Confidence as Patent War and AI Demand Pull Shares in Opposite Directions
The gap between what a company's share price says and what its financial statements reveal can sometimes stretch to breaking...
ASML’s Rally Hits 61% as Buybacks, Bullish Analyst Calls and a Shanghai Rival Collide
The tug-of-war over ASML's share price has produced a striking scoreboard: the Dutch lithography giant has gained 61.32 percent since...
PVA TePla’s order boom fails to offset a weak first-half profit picture
PVA TePla arrived at Thursday’s trading session with a powerful message from its order book: demand is running far ahead...
Infineon’s GaN Patent Victory Meets a 96-Euro Analyst Target: A Halbleiter Stock at the Tipping Point
The Munich-based chipmaker finds itself in an unusual position as it prepares to unveil third-quarter results: a freshly won US...
Aixtron’s 84% Volatility Masks Bull-Bear Schism Ahead of July 30 Earnings Reckoning
Aixtron shares have been on a rollercoaster that leaves even seasoned semiconductor investors gripping the handrails. Annualized volatility on a...
BioNTech’s Triple Pivot: Founders Step Back, Factories Go on the Block, and Oncology Data Looms
Ugur Sahin and Özlem Türeci built BioNTech from a Mainz lab into a global vaccine powerhouse. By the end of...
Infineon Slides 5% as SK Hynix’s Listing Hangover Compounds Technical Weakness During Quiet Period
Infineon’s stock took a sharp hit on Monday, losing 5% to close at €69.17, but the damage originated thousands of...
Ams Osram Closes €570m Infineon Sale, Sets Sights on €40m Interest Savings and 2027 Free Cash Flow Turnaround
Ams Osram has finalized the disposal of its non‑optical analog and mixed‑signal sensor business to Infineon, pocketing €570m in cash...
Aixtron’s High-Wire Act: A €359 Million Backlog Meets Market Skepticism Ahead of July 30
The German semiconductor equipment maker Aixtron presents an increasingly contradictory picture. Its order book has swelled to record levels, two...
BioNTech Faces a Summer of Reckoning as Vaccine Revenues Wane and Oncology Data Takes Center Stage
BioNTech enters a critical stretch with no single event to anchor investor sentiment. The German biotech’s stock closed at €80.20...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
